The Allen Institute, known for foundational neuroscience, launched a new $200 million initiative to translate brain atlas insights into drug development for neurodegenerative diseases including Alzheimer’s. The initiative marks a major step toward pairing large-scale brain mapping with downstream medicinal chemistry and biology. The funding level signals an intent to build capabilities across target discovery, validation, and early-stage development rather than limiting work to basic research. For the broader field, it highlights how atlas-driven biology is moving from characterization toward intervention—an increasingly common strategy as multi-omics and systems neuroscience mature.